Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in Europe and in the US. Its detection is difficult because of the lack of clinical signs and disease-specific biomarkers. As a result, most patients remain asymptomatic and the disease results incurable when it is diagnosed. The PDAC microenvironment is characterized by a thick desmoplastic stroma and disorganized blood vessels that impedes an efficient drug delivery, the accumulation of the drug in the specific site and makes this tumour extremely hard-to-treat with traditional chemotherapy. The progression from normal cells to invasive PDAC requires the accumulation of multiple inherited or acquired mutations.